| Publication rate and citation counts for preprints released during the COVID-19 pandemic: the good, the bad and the ugly D Añazco, B Nicolalde, I Espinosa, J Camacho, M Mushtaq, J Gimenez, ... PeerJ 9, e10927, 2021 | 59 | 2021 |
| Adapting an m-Health intervention for Spanish-speaking Latinx people living with HIV in the nonurban Southern United States TE Flickinger, JE Sherbuk, K Petros de Guex, D Añazco Villarreal, ... Telemedicine Reports 2 (1), 46-55, 2021 | 8 | 2021 |
| Beyond interpretation: the unmet need for linguistically and culturally competent care for Latinx people living with HIV in a Southern region with a low density of Spanish speakers JE Sherbuk, K Petros de Guex, D Anazco Villarreal, S Knight, ... AIDS research and human retroviruses 36 (11), 933-941, 2020 | 8 | 2020 |
| Current pharmacological therapy against COVID-19: a latin american perspective B Nicolalde, D Añazco, M Mushtaq, A Aguilar, E Terán Latin American Journal of Clinical Sciences and Medical Technology 2 (2), 59-68, 2020 | 6 | 2020 |
| Low incidence of pulmonary aspiration during upper endoscopy in patients prescribed a glucagon-like peptide 1 receptor agonist D Anazco, S Fansa, MD Hurtado, M Camilleri, A Acosta Clinical Gastroenterology and Hepatology 22 (6), 1333-1335. e2, 2024 | 3 | 2024 |
| Quantifying alcohol use among Ecuadorian human immunodeficiency virus positive individuals and assessing alcohol as an independent risk factor for human immunodeficiency virus … JM Downen, B Swendener, AA Bodlak, DF Añazco, BI Nicolalde, ... Medicine 99 (48), e23276, 2020 | 3 | 2020 |
| Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study W Ghusn, S Fansa, D Anazco, E Tama, B Nicolalde, K Gala, A De la Rosa, ... International Journal of Obesity, 1-6, 2024 | 2 | 2024 |
| The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes W Ghusn, S Fansa, D Anazco, E Tama, L Cifuentes, K Gala, ... Diabetes, Obesity and Metabolism 26 (6), 2167-2175, 2024 | 1 | 2024 |
| Weight-centric prevention of cancer D Anazco, A Acosta, EJ Cathcart-Rake, SD D'Andre, MD Hurtado Obesity Pillars 10, 100106, 2024 | 1 | 2024 |
| Type 2 Diabetes Remission in Patients with Heterozygous Variants in the Leptin-Melanocortin Pathway after Roux-en-Y Gastric Bypass: A Matched Case–Control Study D Anazco, W Ghusn, A Campos, L Cifuentes, S Fansa, E Tama, JT Bublitz, ... Obesity Surgery 33 (11), 3502-3509, 2023 | 1 | 2023 |
| FRI077 Efficacy of anti-obesity medications among breast cancer survivors taking aromatase inhibitors S Fansa, W Ghusn, E Tama, B Nicolalde, D Anazco, S D'Andre, S Faubion, ... Journal of the Endocrine Society 7 (Supplement_1), bvad114. 087, 2023 | 1 | 2023 |
| The effect of heterozygous gene variants of the leptin-melanocortin pathway on weight loss following sleeve gastrectomy F Feris, W Ghusn, A Campos, L Cifuentes, A De la Rosa, D Sacoto, ... Obesity Surgery 33 (7), 2246-2249, 2023 | 1 | 2023 |
| Scientific literacy and preferred resources used by latin American medical students during the COVID-19 pandemic: a multinational survey B Nicolalde, D Añazco, MJ Jaramillo-Cartwright, I Salinas, ... F1000Research 11, 2022 | 1 | 2022 |
| Efficacy of Antiobesity Medications in Patients With Celiac Disease on a Gluten-free Diet: A Retrospective Matched Cohort Study D Anazco, S Fansa, W Ghusn, K Gala, B Nicolalde, E Tama, G Calderon, ... Journal of Clinical Gastroenterology 58 (7), 650-655, 2024 | | 2024 |
| 1660-P: Efficacy and Safety of Tirzepatide for the Treatment of Obesity in Adults with Type 1 Diabetes—The Mayo Clinic Experience E TAMA, D BECHENATI, P BENNETT, A MCNALLY, R RIVERA, S FANSA, ... Diabetes 73 (Supplement_1), 2024 | | 2024 |
| 1707-P: Real-World 12-Month Weight Loss Outcomes of Tirzepatide—The Mayo Clinic Experience S FANSA, E TAMA, N SAFWAN, W GHUSN, D ANAZCO, A ACOSTA, ... Diabetes 73 (Supplement_1), 2024 | | 2024 |
| 234-OR: Performance of a Machine-Learning Gene Risk Score Biomarker to Predict Weight-Loss Response to Tirzepatide and Semaglutide E TAMA, S FANSA, D ANAZCO, R RIVERA, W GHUSN, L CIFUENTES, ... Diabetes 73 (Supplement_1), 2024 | | 2024 |
| EFFICACY OF ANTI-OBESITY MEDICATIONS IN PATIENTS WITH LEPTIN-MELANOCORTIN PATHWAY HETEROZYGOUS VARIANTS POST-ENDOSCOPIC TRANSORAL OUTLET REDUCTION IN ROUX-EN-Y GASTRIC BYPASS K Gala, BA Dayyeh, W Ghusn, S Fansa, D Anazco, J Stutzman, ... Gastrointestinal Endoscopy 99 (6), AB57-AB58, 2024 | | 2024 |
| Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score W Ghusn, D Anazco, S Fansa, E Tama, L Cifuentes, K Gala, G Calderon, ... Eclinicalmedicine 72, 2024 | | 2024 |
| Unraveling the Variability of Human Satiation: Implications for Precision Obesity Management A Acosta, L Cifuentes, D Anazco, T O’Connor, M Hurtado, W Ghusn, ... | | 2024 |
